AI can suggest Covid-19 antivirals from protein sequence alone
IBM model can also find molecules that bind at different sites on target proteins
The uncertainties of my PhD shaped me
Discovering the potential of mangroves and myself
Meet the first deaf, Black woman to earn a Stem doctorate
Amie Fornah Sankoh has persevered from failing primary school in Sierra Leone to gaining a biochemistry PhD in the US
Margaret Faul: ‘Stand for what you think is right’
The pharmaceutical executive on why chemistry clicked for her, and life as a female organic chemist in the drug industry
Glow-in-the-dark proteins offer cheap and fast diagnostic tests
Covid-19 can be detected with the sensitivity of PCR and the ease of lateral flow
Setting drug development speed records
The pandemic treatment sprint was spectacular, but hard to match under less unusual circumstances
Pharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
The end of a long race?
The finishing line of the Covid-19 pandemic may be in sight, but we mustn’t stop running just yet
French inquiry censures lab that promoted hydroxychloroquine to treat Covid
Report raises awkward questions about prominent study on antimalarial conducted in Didier Raoult’s lab
Introduction: the coronavirus pandemic and the future
This series of Chemistry World reports is part of a forth coming e-book and hardback to be published by the Royal Society of Chemistry. The book was motivated by a desire on the part of the editors and the authors to produce a body of information on the new and deadly coronavirus about which the world was largely uninformed and for which it was totally unprepared.
Favipiravir
Originally developed to treat flu and marketed in Japan as Avigan, promising Covid-19 trial results have seen countries stockpiling this medication by the millions
Source: © StreetVJ / Shutterstock.com
Angela Russell: ‘We have to not be afraid of failing’
The medicinal chemist on thinking like a scientist and knowing where you want to go
Protective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
Medical research charities report £260 million shortfall due to pandemic
The impact of Covid-19 on fundraising efforts sees charities slash research support
New questions raised over Sputnik Covid vaccine results point to fraudulent practices
Analysis comparing Sputnik results with five other Covid vaccines finds phase 3 trial outcome is highly improbable
Catalogues of complexity
The tangled web of fine chemicals supply frequently throws up surprises
Teaching-focused staff contribute to REF results too
But are often overlooked in celebrations of research excellence
What is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment
UK’s non-profit vaccine manufacturing centre sold off before opening
Pharmaceutical firm Catalent buys government-backed facility near Oxford
Moderna sued over Covid-19 vaccine-related patents
Arbutus and Genevant say lipid nanoparticles that protect mRNA infringe six key patents
Can we clean Covid from the air around us?
The human health observatory in our sewers
mRNA vaccines for Covid and beyond
Experimenting in a pandemic
2020: the year the world changed
Supporting the chemistry community
- Previous
- Next
Pharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
Covid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
New antiviral impresses against Covid-19
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
Where are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
Leading a lab through pandemic-induced uncertainty
Emphathy is vital to support mentees effectively
Let it go
We have to accept that we can’t catch up on time lost in lockdown
Chemistry Nobel predictions range from free-radical chemistry to MOFs
Data-crunching goes up against gut feeling as the chemistry community weighs in on their favourites for the world’s top chemistry prize
Lights, smartphones, action!
How an intrepid group of technicians adventured into the world of filmmaking
The future of ‘next generation’ DNA sequencing
As it gets cheaper and easier to read genetic code, its applications are expanding rapidly
Remotely of value?
The benefits and drawbacks of working or studying from home are not clear cut
US intelligence can’t agree if Covid-19 came from an animal or a lab
After months of investigation agencies remain divided on most likely origin of Sars-CoV-2
US grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
Virtual modality
Moving science events online during Covid-19
The multi-pronged search for Covid-19 treatments
Drugs that block infection or reduce inflammation will complement vaccine protection
Pandemic continues to disrupt and depress UK researchers, survey finds
Researchers reported spending more time on peer-review activities, teaching and writing
Developing countries sidelined in Covid-19 vaccine scramble
Lack of funds and local manufacturing capacity has prevented Covax from competing with wealthier nations’ self-interest
Molly Shoichet: ‘We fail every day’
The Canadian biomedical engineer on failure, politics and celebrity science
Race to understand Sars-CoV-2 variants amid fears virus might evade vaccines
Biochemical basis behind coronavirus variants’ success could hold key to defeating them
